ExoStemTech

Based in South Korea, ExoStemTech specializes in the development and production of exosome-based therapeutics derived from adult stem cells, aiming to address various medical conditions through innovative solutions. Founded in 2016 and headquartered in Ansan, South Korea, ExoStemTech focuses on exosome technology for therapeutic applications in regenerative medicine. The company was established by Yong-woo Cho, who has a history in biopharmaceutical ventures. ExoStemTech has successfully completed 4 funding deals to date, with the latest being a Series B round in December 2021, raising KRW 999.

996 mn from Daewoong Pharmaceutical, bringing the total amount raised to KRW 999. 996 mn and a current valuation of KRW 84,273. 348 mn. ExoStemTech specializes in the production of exosomes derived from adult stem cells, along with functional exosomes that possess enhanced therapeutic efficacy.

Their core offerings include proprietary therapeutics branded as CARTISOME®, BEIGESOME®, EST-T-EXO, OSTEOSOME®, HEPATOSOME®, and HYPOXISOME®, targeting conditions such as osteoarthritis, obesity, diabetes, liver disease, and cancer. The company's technological platforms facilitate the mass production of high-quality exosomes for clinical applications, serving a global market with a focus on regions advancing stem cell research and therapeutic applications, including Asia, Europe, and North America. ExoStemTech’s revenue model focuses on the commercialization of its exosome-based therapeutics through direct sales to healthcare providers, research institutions, and pharmaceutical partners. The company engages in B2B transactions, supplying hospitals and clinics with its flagship products for treatment protocols, especially in regenerative medicine and chronic disease management.

The pricing strategy reflects the unique therapeutic benefits and advanced technology behind their products, maintaining a competitive position in the biopharmaceutical industry. ExoStemTech plans to utilize the KRW 999. 996 mn raised in the Series B funding round to establish exosome extraction and purification technologies and develop new exosome treatments. Future growth strategies include launching upcoming products designed to enhance treatment efficacy and expanding into new geographic markets, specifically targeting regions with increasing demand for advanced therapeutic solutions.

The company aims to advance its presence in Asia, Europe, and North America by the end of 2025.